Lateral Pharma commenced operations in May 2015, with a focus on repurposing LAT8881; an orally-available compound with extensive human safety data, into new high potential indications. LAT8881 (Tyr-hGH177-191) is a 16 amino acid peptide fragment based on the C-terminus of human-growth hormone (hGH177-191) with an additional tyrosine at the N-terminus. LAT8881 was initially developed for the treatment of obesity, but clinical studies did not show a statistically significant weight loss in obese subjects, and development for this indication was discontinued.
Since commencing its operations in 2015, Lateral has progressed the clinical development of LAT8881 by testing it in a variety of animal models of neuropathic pain. In vivo studies demonstrated an analgesic effect when orally dosing with LAT8881, and in vitro electrophysiological studies suggested that LAT8881 inhibits neuronal activity in a manner consistent with a reduction in pain signalling.
Owing to these promising preclinical data, a unique mechanism of action, and its demonstrated tolerability and lack of known addictive properties, LAT8881 represented a highly attractive proposition as a therapeutic agent for pain indications. Accordingly, Lateral continued to progress the clinical development of LAT8881, and in 2019 sponsored two Phase II clinical trials in neuropathic pain, and migraine. Both trials were open to recruitment in 2019, have since met their respective targets in Q1 2020, and the preliminary results will be available by Q3 2020.